Butterfly, Graham, Wise Equity target nutraceuticals; Demand for antimicrobial testing drives Astorg’s $1bn carve-out of Thermo Fishers’ microbiology biz
Butterfly Equity, Graham Partners and Wise Equity are among the firms transacting with nutraceuticals assets. The post Butterfly, Graham, Wise Equity target nutraceuticals; Demand for antimicrobial testing drives Astorg’s $1bn carve-out of Thermo Fishers’ microbiology biz appeared first on PE Hub .
We haven't written up this one. PE Hub has the full story — the link below goes straight to it.
